Tesetaxel as First-line Therapy for Metastatic Breast Cancer

Status Recruiting

Clinical Trial Summary

The intravenously administered taxane, paclitaxel, is one of the most commonly employed agents for the treatment of both localized and advanced breast cancer.

Tesetaxel is an orally administered taxane that is in development as first- and second-line treatment for patients with advanced cancers. This study is being undertaken to determine the efficacy and safety of tesetaxel administered as first-line therapy to patients with metastatic breast cancer.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01221870
Study type	Interventional
Source	Genta Incorporated
Contact
Status	Recruiting
Phase	Phase 2
Start date	November 2010
Completion date	January 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03273426` - Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.	N/A
Recruiting	`NCT04583124` - Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO)	N/A
Active, not recruiting	`NCT04489173` - TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer	Phase 2
Recruiting	`NCT02913573` - Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction	Phase 2
Completed	`NCT03124095` - Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer	N/A
Terminated	`NCT00251095` - Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer	Phase 3
Completed	`NCT05576545` - Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment	N/A
Active, not recruiting	`NCT03625635` - Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment	N/A
Recruiting	`NCT04799535` - Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
Withdrawn	`NCT03266562` - Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography	N/A
Completed	`NCT00530868` - Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer	Phase 2
Recruiting	`NCT06255808` - Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
Completed	`NCT04640220` - Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors	N/A
Completed	`NCT02970682` - SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer	Phase 2
Completed	`NCT02316561` - Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer	N/A
Terminated	`NCT00638963` - Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)	Phase 2
Terminated	`NCT00249301` - A Study of MLN8054 in Patients With Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT06056414` - Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation	N/A
Recruiting	`NCT05427071` - Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy	N/A
Recruiting	`NCT03740893` - PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer	Phase 2